The safety of extended-release drug formulations for the treatment of ADHD.

about

Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature.

P2860

Q47667525-41FA416A-2236-4488-8BB7-7685CC3DC18B

P2860

The safety of extended-release drug formulations for the treatment of ADHD.

Item

http://www.wikidata.org/entity/Q38732635

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The safety of extended-release drug formulations for the treatment of ADHD.

@en

type

Item

label

The safety of extended-release drug formulations for the treatment of ADHD.

@en

prefLabel

The safety of extended-release drug formulations for the treatment of ADHD.

@en

P1476

The safety of extended-release drug formulations for the treatment of ADHD.

@en

P2093

Ann Childress

http://www.w3.org/2001/XMLSchema#string

P2860

Amphetamine, past and present--a pharmacological and clinical perspective

ADHD drugs and serious cardiovascular events in children and young adults

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.

Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis.

Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.

P304

603-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1317344

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28393639

http://www.w3.org/2001/XMLSchema#string

The safety of extended-release drug formulations for the treatment of ADHD.

about

P2860

P2860

The safety of extended-release drug formulations for the treatment of ADHD.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698